vs

Side-by-side financial comparison of CervoMed Inc. (CRVO) and REZOLVE AI PLC (RZLV). Click either name above to swap in a different company.

CervoMed Inc. is the larger business by last-quarter revenue ($1.8M vs $1.2M, roughly 1.5× REZOLVE AI PLC). CervoMed Inc. runs the higher net margin — -356.1% vs -1078.8%, a 722.7% gap on every dollar of revenue.

CervoMed Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative conditions such as Alzheimer’s disease and other forms of dementia. It operates in the global biopharmaceutical market, with core R&D segments dedicated to addressing unmet medical needs for patients with progressive brain disorders.

REZOLVE AI PLC is a UK-based technology firm developing AI-powered mobile engagement and instant transaction platforms. Its solutions let consumers complete purchases directly from audio, video, and print content, serving retail, consumer goods, and media clients across Europe, North America, and select APAC markets.

CRVO vs RZLV — Head-to-Head

Bigger by revenue
CRVO
CRVO
1.5× larger
CRVO
$1.8M
$1.2M
RZLV
Higher net margin
CRVO
CRVO
722.7% more per $
CRVO
-356.1%
-1078.8%
RZLV

Income Statement — Q2 FY2025 vs Q2 FY2025

Metric
CRVO
CRVO
RZLV
RZLV
Revenue
$1.8M
$1.2M
Net Profit
$-6.3M
$-13.0M
Gross Margin
Operating Margin
-376.4%
-808.4%
Net Margin
-356.1%
-1078.8%
Revenue YoY
-46.6%
Net Profit YoY
-170.1%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRVO
CRVO
RZLV
RZLV
Q2 25
$1.8M
$1.2M
Q1 25
$1.9M
Q4 24
$2.2M
Q3 24
$1.9M
Q2 24
$3.3M
Q1 24
$2.3M
Q4 23
$2.5M
Q3 23
$1.5M
Net Profit
CRVO
CRVO
RZLV
RZLV
Q2 25
$-6.3M
$-13.0M
Q1 25
$-4.9M
Q4 24
$-6.7M
Q3 24
$-4.8M
Q2 24
$-2.3M
Q1 24
$-2.5M
Q4 23
$-2.4M
Q3 23
$2.2M
Operating Margin
CRVO
CRVO
RZLV
RZLV
Q2 25
-376.4%
-808.4%
Q1 25
-276.6%
Q4 24
-334.9%
Q3 24
-278.2%
Q2 24
-91.1%
Q1 24
-110.6%
Q4 23
-99.6%
Q3 23
-175.2%
Net Margin
CRVO
CRVO
RZLV
RZLV
Q2 25
-356.1%
-1078.8%
Q1 25
-255.2%
Q4 24
-310.2%
Q3 24
-245.1%
Q2 24
-70.4%
Q1 24
-107.1%
Q4 23
-94.9%
Q3 23
140.9%
EPS (diluted)
CRVO
CRVO
RZLV
RZLV
Q2 25
Q1 25
Q4 24
Q3 24
$-0.55
Q2 24
Q1 24
Q4 23
Q3 23
$-0.70

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRVO
CRVO
RZLV
RZLV
Cash + ST InvestmentsLiquidity on hand
$33.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$33.4M
$-14.3M
Total Assets
$38.1M
$80.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRVO
CRVO
RZLV
RZLV
Q2 25
$33.5M
Q1 25
$35.2M
Q4 24
$38.9M
Q3 24
$46.7M
Q2 24
$45.1M
Q1 24
$6.4M
Q4 23
$7.8M
Q3 23
$10.4M
Stockholders' Equity
CRVO
CRVO
RZLV
RZLV
Q2 25
$33.4M
$-14.3M
Q1 25
$34.6M
Q4 24
$39.2M
Q3 24
$45.6M
Q2 24
$50.0M
Q1 24
$5.3M
Q4 23
$7.4M
Q3 23
$9.6M
Total Assets
CRVO
CRVO
RZLV
RZLV
Q2 25
$38.1M
$80.1M
Q1 25
$38.6M
Q4 24
$43.1M
Q3 24
$48.9M
Q2 24
$53.2M
Q1 24
$8.0M
Q4 23
$10.0M
Q3 23
$12.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRVO
CRVO
RZLV
RZLV
Operating Cash FlowLast quarter
$-6.5M
$-4.9M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRVO
CRVO
RZLV
RZLV
Q2 25
$-6.5M
$-4.9M
Q1 25
$-3.9M
Q4 24
$-8.1M
Q3 24
$-4.9M
Q2 24
$-2.2M
Q1 24
$-1.4M
Q4 23
$-2.5M
Q3 23
$-1.5M
Cash Conversion
CRVO
CRVO
RZLV
RZLV
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23
Q3 23
-0.68×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons